Physician profile
Nathan E Langer
NPI 1225230030
$7,007.72
in general payments reported to CMS, 2019-2025
63 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $84.45 · 2021: $104 · 2022: $930 · 2023: $1,696 · 2024: $2,032 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,523 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,523.03 |
| Education | $254.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $698.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $508.16 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Pfizer INC. | $462.29 | 2019-2025 | |
| Genentech USA, INC. | $451.49 | 2021-2025 | Tecentriq, Polivy, Rozlytrek |
| Eisai INC. | $373.23 | 2022-2025 | |
| Janssen Biotech, INC. | $364.59 | 2020-2025 | Imbruvica, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $287.89 | 2022-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $287.73 | 2022-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $207.02 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $183.09 | 2023-2025 | |
| Taiho Oncology, INC. | $155.71 | 2022-2025 | |
| Daiichi Sankyo INC. | $134.99 | 2023-2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $127.92 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $123.60 | 2022-2025 | Alunbrig, Fruzaqla |
| Rigel Pharmaceuticals, INC. | $120.42 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $114.16 | 2019-2023 | Tivdak, Tukysa |
| Beone Medicines USA, INC. | $103.26 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $101.92 | 2021-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $99.95 | 2024 | |
| Servier Pharmaceuticals LLC | $99.52 | 2022-2024 | |
| Genzyme Corporation | $98.57 | 2023-2025 | |
| Abbvie INC. | $96.70 | 2022-2025 | |
| Mirati Therapeutics, INC. | $84.56 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $79.40 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $79.36 | 2023-2025 | Zoladex, Xermelo |
| Stemline Therapeutics INC. | $75.94 | 2023-2024 | Orserdu, Elzonris |
| Jazz Pharmaceuticals INC. | $75.48 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $74.58 | 2022-2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.24 | 2022-2025 | |
| Emd Serono, INC. | $73.47 | 2022-2024 | Bavencio |
| Sobi, INC | $65.45 | 2023-2024 | |
| Novocure INC. | $63.43 | 2019-2025 | Optune, Optune Lua (Novottf-200t) |
| Incyte Corporation | $62.48 | 2023 | Monjuvi, Pemazyre, Jakafi |
| Array Biopharma INC | $59.90 | 2023-2024 | Mektovi, Lorbrena, Braftovi |
| Astellas Pharma US INC | $57.15 | 2020-2022 | |
| Puma Biotechnology, INC. | $53.24 | 2021-2025 | |
| Genmab U.S., INC. | $53.18 | 2024-2025 | Epkinly |
| Atricure, INC. | $48.17 | 2021 | |
| Adc Therapeutics America, INC. | $45.45 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $45.37 | 2024-2025 | Xarelto |
| Sumitomo Pharma America, INC. | $44.92 | 2023-2025 | Orgovyx |
| Amgen INC. | $41.65 | 2022-2023 | Lumakras |
| Beigene USA, INC. | $40.79 | 2023-2024 | Brukinsa |
| Celgene Corporation | $36.62 | 2023 | Pomalyst |
| Apellis Pharmaceuticals, INC. | $36.03 | 2022-2024 | Empaveli |
| Gilead Sciences, INC. | $35.36 | 2021-2024 | |
| Iovance Biotherapeutics, INC. | $34.50 | 2025 | Amtagvi |
| Dendreon Pharmaceuticals LLC | $29.92 | 2022 | |
| Legend Biotech USA INC. | $29.23 | 2025 | Carvykti |
| Azurity Pharmaceuticals, INC. | $27.93 | 2025 | Danziten, Vivimusta |
| Alnylam Pharmaceuticals INC. | $27.25 | 2024 | Givlaari |
| Adaptive Biotechnologies Corporation | $24.86 | 2025 | Clonoseq |
| Lilly USA, LLC | $24.76 | 2023 | Verzenio, Retevmo, Jaypirca |
| Blueprint Medicines Corporation | $23.58 | 2024 | Ayvakit |
| Springworks Therapeutics, INC. | $23.48 | 2024 | Ogsiveo |
| Blue Earth Diagnostics | $22.03 | 2023 | |
| Aveo Pharmaceuticals, INC. | $21.61 | 2023 | Fotivda |
| Cti Biopharma Corp. | $20.51 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.08 | 2022 | |
| G1 Therapeutics, INC. | $19.63 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $18.59 | 2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $18.36 | 2023 | Xpovio |
| Kyowa Kirin, INC. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Langer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.